Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse MKT  >  Navidea Biopharmaceuticals Inc    NAVB

NAVIDEA BIOPHARMACEUTICALS INC (NAVB)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Navidea Biopharmaceuticals : Management to Host Moderated Q&A Webcast to Provide Corporate Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2018 | 11:48pm CEST

Webcast will also focus on Proxy Updates

Navidea Biopharmaceuticals (NYSE American: NAVB) (Navidea or The Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that it will hold an online Question & Answer (Q&A) Session focused on Navidea’s corporate progress as well as an update on the corporate proxy with Jed Latkin, Chief Financial and Operating Officer, and Michael M. Goldberg, M.D., President and Chief Executive Officer of Navidea, on Thursday July 19, 2018 at 5:00 p.m. Eastern Time.

 
Event: Navidea IR Q&A Session – July 2018
Date: Thursday, July 19, 2018
Time: 5:00 p.m. Eastern Time
Website:

www.navidea.com

For the July IR-focused Q&A Session, Navidea invites all interested investors to submit questions they would like to see asked by Wednesday, July 18, 2018 to ir@navidea.com or jgreen@edisongroup.com.

Details for the webcast link will be made available on the Investor Relations section of Navidea’s website at www.navidea.com.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. The development activities of the Manocept immunotherapeutic platform are being conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts.

For more information, please visit http://www.navidea.com.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NAVIDEA BIOPHARMACEUTICALS
09/19NAVIDEA BIOPHARMACEUTICALS : Announces Acceptance into the National Institutes o..
AQ
09/19NAVIDEA BIOPHARMACEUTICALS : Announces Closing of a $3 Million Private Placement
AQ
09/18NAVIDEA BIOPHARMACEUTICALS : get NIH nod, shares bolt
AQ
09/17NAVIDEA BIOPHARMACEUTICALS : Announces Acceptance into the National Institutes o..
BU
09/17NAVIDEA BIOPHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, F..
AQ
09/17NAVIDEA BIOPHARMACEUTICALS : Announces Closing of a $3 Million Private Placement
BU
08/23NAVIDEA BIOPHARMACEUTICALS : Receives Noncompliance Notice From NYSE American
AQ
08/21NAVIDEA BIOPHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security H..
AQ
08/21NAVIDEA BIOPHARMACEUTICALS : Announces Results of the Annual Shareholder Meeting
AQ
08/20NAVIDEA BIOPHARMACEUTICALS : Receives Noncompliance Notice From NYSE American
AQ
More news
News from SeekingAlpha
08/16Navidea Biopharmaceuticals' (NAVB) Interim CEO Jed Latkin on Q2 2018 Results .. 
08/09Navidea Biopharm reports Q2 results 
05/09Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Q1 2018 Results - .. 
05/08Navidea Biopharm reports Q1 results 
05/02Cirius Therapeutics completes enrollment in mid-stage study of lead candidate.. 
Chart NAVIDEA BIOPHARMACEUTICALS INC
Duration : Period :
Navidea Biopharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Jed Andrew Latkin CEO, COO, CFO, Secretary, Director & Treasurer
Frederick O. Cope Chief Scientific Officer & Senior Vice President
Michael Yehuda Rice Independent Director
Claudine E. Bruck Director
Sector and Competitors
1st jan.Capitalization (M$)
NAVIDEA BIOPHARMACEUTICALS INC-35.82%38
CELLTRION, INC.--.--%34 265
IQVIA HOLDINGS INC27.92%25 370
LONZA GROUP21.88%24 695
INCYTE CORPORATION-28.39%14 296
SEATTLE GENETICS, INC.45.25%12 306